Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
A protective effect of angiotensin-converting enzyme (ACE) inhibitors has been shown in patients with diabetic nephropathy but has not been clearly established in nondiabetic renal disease. A multicenter European study was designed to determine whether the ACE inhibitor benazepril was safe and effective in protecting residual renal function in patients with various renal diseases and mild to moderate renal failure. The trial involved 583 patients from 49 centers in Italy, France, and Germany. The patients were randomized to receive benazepril or placebo plus other antihypertensive agents, the target being a diastolic blood pressure of less than 90 mm Hg. Thirty-one patients in the benazepril group and 57 patients in the placebo group reached the end point [the time elapsed from entry to (a) doubling of serum creatinine (SCr) concentrations and (b) start of renal replacement therapy; p < 0.001 at 3 years]. The associated reduction in the relative risk of reaching the end point was 53% in benazepril-treated patients, with actuarial renal survival probability significantly better at 3 years. The best survival of renal function was observed in patients with chronic glomerular diseases and proteinuria greater than 1.0 g/24 h. Benazepril is effective in slowing the rate of progression and improving the survival of renal function in patients with renal diseases of various origins. This protective effect is associated with a clinically relevant decrease in both blood pressure and proteinuria.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The bene fi ts of ACEi/ARB therapy are also supported by data extrapolated from larger studies that have included a broader range of patients with nondiabetic kidney disease and albuminuria. 25,26”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [26]
Citations
Cites
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Self-citationIs glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?
Remuzzi, G., & Bertani, T. (1990) · Kidney International · doi:10.1038/ki.1990.217 · Cited by 397
Long-term comparison between captopril and nifedipine in the progression of renal insufficiency
Zucchelli, P., Zuccalà, A., Borghi, M., Fusaroli, M., Sasdelli, M., Stallone, C., Sanna, G., & Gaggi, R. (1992) · Kidney International · doi:10.1038/ki.1992.309 · Cited by 270
Self-citationRandomised controlled trial of enalapril and β blockers in non- diabetic chronic renal failure
Hannedouche, T., Landais, P., Goldfarb, B., Esper, N. E., Fournier, A., Godin, M., Durand, D., Chanard, J., Mignon, F., Suc, J.-M., et al. (1994) · BMJ · doi:10.1136/bmj.309.6958.833 · Cited by 220
Proteinuria and blood pressure as causal components of progression to end-stage renal failure
Locatelli, F., Marcelli, D., Comelli, M., Alberti, D., Graziani, G., Buccianti, G., Redaelli, B., Giangrande, A., & Italy the Northern Italian Cooperative Study Group (1996) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/11.3.461 · Cited by 191
Self-citationEffect of Enalapril on the Progression of Chronic Renal Failure
Kamper, A.-L., Strandgaard, S., & Leyssac, P. P. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.7.423 · Cited by 163
Praga, M., Hernández, E., Montoyo, C., Andrés, A., Ruilope, L. M., & Rodicio, J. L. (1992) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80696-2 · Cited by 132
Yusuf, S., Held, P., Teo, K. K., & Toretsky, E. R. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090114 · Cited by 121
Research works printed but not linked: 4
- Apperloo, 1994, Kidney Int, 45, S174
- Becker, 1994, Kidney Int, 45, S167
- Peterson, 1993, J Am Soc Nephrol, 4, 254A
- Gansevoort, 1994, J Am Soc Nephrol, 5, 329A
Cited by
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Self-citationNakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 970
RetractedWheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
Management of Hypertension in Chronic Kidney Disease
Pugh, D., Gallacher, P. J., & Dhaun, N. (2019) · Drugs · doi:10.1007/s40265-019-1064-1 · Cited by 401
Knowles, J. W., Reddick, R. L., Jennette, J. C., Shesely, E. G., Smithies, O., & Maeda, N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8376 · Cited by 305
Metadata
- Authors
- Maschio, G., Alberti, D., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., Janin, G., & Zucchelli, P.
- Affiliations
- IRCCS Humanitas Research Hospital (IT)
- Heidelberg University (DE)
- University of Bologna (IT)
- Corresponding author
- Maschio, G.
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 1999
- Volume
- 33
- Pages
- S16-S20
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W2035875362
- Cited by
- 77
- References
- 11
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 2 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 2
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cardiovascular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Keywords
- ACE inhibitors, benazepril, renal protection, chronic kidney disease, renal function decline, proteinuria, glomerular disease, antihypertensive therapy, blood pressure reduction, renal survival, diabetic nephropathy
- MeSH terms
- Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzazepines, Blood Pressure, Creatinine, Female, Humans, Kidney Diseases, Male, Placebos, Prospective Studies, Proteinuria, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial. https://app.cochat.ai/papers/10.1097/00005344-199900001-00004
- The paper
- Maschio, G., Alberti, D., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., Janin, G., & Zucchelli, P. (1999). Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/00005344-199900001-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.